[Prognostic significance of flow cytophotometric studies in ovarian cancer]

other OA: closed public-domain-us
View on PubMed View at publisher

Abstract

Prognostic significance of DNA content and of distribution of cell cycle phases in ovarian carcinomas (stage III and IV) were investigated using flow cytometry. From 37 tumors 15 had DNA indices less than 2.5 and 22 had DNA indices greater than or equal to 2.5 (diploid = 2). Patients with diploid or near diploid tumors had significantly longer survival times than those with aneuploid tumors (DNA indices greater than 2.5) (log-rank test, p = 0.009, rank-sum test, p = 0.011). Patients whose tumors showed a high proportion of S/G2/M-phase cells (greater than 17%) had shorter survival times than those with tumors with a lower proportion of S/G2/M-phase cells (log-rank test p = 0.009, rank-sum test p = 0.022). The median length of follow-up of the patients was 4 years. Thus, our experiments have shown that measurements of DNA ploidy and proliferative activity using flow cytometry are important prognostic indicators for patients with ovarian carcinomas. In the future these factors might play an important role for the prognosis of patients with ovarian carcinomas. In addition, there exists a tendency for patients with in vitro resistant tumors to die earlier than those with sensitive tumors, but these results were not significant (log-rank test, p = 0.16; rank-sum test, p = 0.059).

My notes (saved in your browser only)

Condition tags

endometriosisdie_deep_infiltrating

MeSH descriptors

Flow Cytometry Ovarian Neoplasms Adult Aged Carcinoma Carcinoma Carcinoma, Papillary Carcinoma, Papillary DNA, Neoplasm DNA, Neoplasm Endometriosis Endometriosis Female Humans Interphase Middle Aged Ovarian Neoplasms Ovary Ovary Prognosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-19T06:14:56.452680+00:00
pubmed
last seen: 2026-05-13T22:09:30.565292+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine